Book Cover
Home  |   Chemicals & Materials   |  Chiral Chemicals Market

Chiral Chemicals Market Size, Share, Growth, and Industry Analysis, By Type (Traditional Separation Method, Asymmetric Preparation Method, Biological Separation Method), By Application (Pharmaceuticals, Agrochemicals, Flavors/Fragrances), Regional Insights and Forecast to 2035

Trust Icon
1000+
GLOBAL LEADERS TRUST US

Chiral Chemicals Market Overview

The global Chiral Chemicals Market is anticipated to grow from USD 80438.6 Million in 2026 to USD 213478.25 Million by 2035, registering a CAGR of 11.45% during the forecast period 2026-2035.

Metric Value
Largest region North America (36%)
Largest application Pharmaceuticals (72%)
Largest type Asymmetric Preparation Method (48%)
Fastest-moving product trend Engineered enzyme biocatalysis, asymmetric synthesis, and continuous flow chemistry for high-purity chiral compounds
Leading companies BASF (14.6%), Johnson Matthey (12.4%)

Chiral chemicals are molecular compounds that exist as non-superimposable mirror images, known as enantiomers, where each form can exhibit dramatically different biological, pharmacological and toxicological properties despite sharing identical chemical formulas. The pharmaceutical industry's sustained drive toward single-enantiomer drug development, driven by regulatory pressure and superior therapeutic profiles, has established chiral chemicals as one of the most strategically important categories in fine chemical manufacturing. An estimated 56% of all currently marketed pharmaceutical drugs are chiral compounds, and the proportion of new drug approvals incorporating chiral active ingredients continues to rise as drug developers prioritise enantiomeric purity to improve efficacy and reduce adverse effect profiles. Advances in asymmetric synthesis, enzymatic biocatalysis and chiral chromatographic separation are progressively expanding production possibilities and improving the economics of chiral chemical manufacturing.

In the United States, the chiral chemicals market is underpinned by one of the world's most active pharmaceutical research and development ecosystems, where regulatory requirements for enantiomeric purity documentation have been firmly established for decades. The FDA's longstanding guidance on the development of stereoisomeric drugs has created a well-defined regulatory framework that makes single-enantiomer development the standard approach for new chiral drug candidates, supporting consistent and growing demand for high-purity chiral intermediates and active pharmaceutical ingredients. Major producers including BASF, Johnson Matthey, Codexis and Chiral Technologies serve the US pharmaceutical and agrochemical markets through both bulk chemical supply and custom synthesis service models, with demand driven by both domestic drug manufacturing and the country's large contract research and manufacturing organisation sector.

Global Chiral Chemicals Market Size, 2035 (USD Million)

Get Comprehensive Insights into the Market’s Size and Growth Trends

downloadDownload FREE Sample

Key Findings

  • Market Driver: Expanding pharmaceutical single-enantiomer drug development is the most influential growth driver, with approximately 56% of currently marketed pharmaceutical drugs being chiral compounds and the share of chiral new drug approvals continuing to rise globally.
  • Major Market Restraint: High production costs for asymmetric preparation methods remain the leading restraint, with enantioselective synthesis processes adding approximately 25% to active pharmaceutical ingredient production costs compared with racemic mixture manufacturing routes.
  • Emerging Trends: Biocatalytic asymmetric synthesis using engineered enzymes is reshaping production economics, with next-generation biocatalysis achieving enantiomeric excess values above 99% while reducing process waste by approximately 35% compared with conventional chemical asymmetric methods.
  • Regional Leadership: North America is expected to lead with approximately 36% of global market share, driven by its dominant pharmaceutical R&D base, established regulatory framework for chiral drug purity and a large contract manufacturing sector with extensive chiral synthesis capability.
  • Competitive Landscape: Codexis expanded its engineered enzyme platform for pharmaceutical chiral synthesis, with new biocatalyst variants projected to reduce manufacturing steps by approximately 30% for key chiral active pharmaceutical ingredient production routes.
  • Market Segmentation: Asymmetric Preparation Method is projected to hold the largest share at approximately 48%, while Pharmaceuticals dominate application demand with an estimated 72% of total chiral chemicals consumption globally across both synthesis and separation applications.
  • Recent Development: Johnson Matthey launched an advanced asymmetric hydrogenation catalyst platform, with process validation data demonstrating a 20% improvement in enantiomeric excess consistency across production scale batches compared with the previous generation catalyst system.

The Chiral Chemicals Market is witnessing rapid advancements in biocatalytic synthesis technologies, improving efficiency and sustainability in pharmaceutical intermediate production. Engineered enzymes are achieving enantiomeric excess values above 99% under controlled reaction conditions. Biocatalytic processes have demonstrated an estimated 35% reduction in process waste compared with conventional asymmetric synthesis methods. Increasing adoption of continuous flow chemistry is further improving reaction precision, reducing energy consumption, and supporting environmentally sustainable manufacturing.

Growing demand for single-enantiomer agrochemicals is emerging as another important trend in the Chiral Chemicals Market. Manufacturers are developing advanced chiral formulations that improve pesticide effectiveness while reducing application rates and environmental impact. Approximately 18% of new agrochemical active ingredients undergoing regulatory review contain chiral centres, reflecting increasing industry adoption. Stricter pesticide regulations and growing emphasis on enantiomeric purity are encouraging innovation in sustainable agrochemical production.

Market Dynamics

Driver

"Pharmaceutical single-enantiomer drug development and regulatory purity requirements are sustaining strong chiral chemical demand."

The pharmaceutical industry's commitment to single-enantiomer drug development is the most powerful and durable driver of chiral chemical demand. Regulatory agencies including the FDA and EMA require comprehensive stereochemical characterisation of new drug candidates, and the superior therapeutic profiles of single-enantiomer drugs compared with racemic mixtures make enantiomeric purity a competitive advantage as well as a regulatory obligation. An estimated 56% of all currently marketed pharmaceutical drugs are chiral compounds, and the pharmaceutical pipeline consistently shows that the majority of new chiral drug approvals specify single-enantiomer active ingredients rather than racemic mixtures.

The chiral switch strategy, where existing racemic drugs are redeveloped as single-enantiomer products to extend patent protection and improve clinical profiles, continues to generate demand for chiral synthesis and separation capability beyond entirely new drug development. This strategy has been applied successfully across multiple therapeutic categories, and the commercial incentive to pursue chiral switch opportunities for off-patent racemic drugs remains relevant as pharmaceutical companies seek to leverage existing clinical knowledge bases with improved enantiomeric purity profiles that support new intellectual property positions.

Restraint

"High production costs and technical complexity of chiral synthesis are limiting adoption in cost-sensitive applications."

The production of single-enantiomer chemicals through asymmetric preparation methods involves sophisticated catalysts, specialised process equipment and precise reaction control that adds substantially to manufacturing cost compared with racemic production routes. Enantioselective synthesis can add approximately 25% to active pharmaceutical ingredient production costs, and this premium is a meaningful constraint for generic pharmaceutical manufacturers and for agrochemical producers operating in highly price-competitive markets where input cost management directly determines profitability.

Scaling chiral synthesis processes from laboratory to commercial production introduces additional technical challenges. Enantioselective reactions are often sensitive to temperature, solvent conditions and reactant concentration in ways that complicate scale-up, and maintaining the enantiomeric excess achieved in laboratory development at commercial production scale requires extensive process optimisation investment. The technical expertise required for this optimisation work is concentrated in a relatively small number of specialist chemistry organisations, creating a skilled workforce bottleneck that limits how quickly the industry can expand chiral manufacturing capacity in response to growing demand.

Opportunity

"Biocatalysis technology advancement and agrochemical sector adoption are creating significant new chiral market opportunities."

The rapid improvement of engineered enzyme technologies for asymmetric synthesis is creating a substantial commercial opportunity to replace cost-intensive chemical asymmetric methods with more efficient biocatalytic routes for a growing range of chiral pharmaceutical intermediates. Directed evolution and AI-assisted protein engineering are dramatically accelerating the development of novel enzymes capable of catalysing previously inaccessible chiral transformations, and the commercial availability of custom-engineered biocatalysts through companies including Codexis and W. R. Grace is making biocatalytic chiral synthesis accessible to pharmaceutical manufacturers without in-house enzyme development capability.

The agrochemical sector's transition toward single-enantiomer active ingredients represents a second major opportunity. An estimated 18% of new agrochemical active ingredients in regulatory review contain chiral centres, and the environmental and regulatory advantages of single-enantiomer formulations are driving increasing investment in chiral agrochemical development. Producers including Bayer and BASF are actively exploring enantioselective synthesis routes for new agrochemical development programmes, creating demand for chiral catalyst and biocatalyst supply alongside the finished chiral chemical production market.

Challenge

"Intellectual property complexity and catalyst supply chain concentration are creating strategic vulnerabilities for chiral producers."

The chiral chemicals market is characterised by extensive intellectual property coverage on both asymmetric synthesis methods and the chiral catalysts used to implement them. Proprietary chiral ligands, transition metal catalyst systems and biocatalyst sequences are protected by overlapping patent portfolios held by a small number of leading organisations including Johnson Matthey, Solvias and Chiral Technologies, and accessing the most effective chiral synthesis routes for specific chemical targets may require licensing arrangements that add cost and administrative complexity to manufacturing programmes.

Precious metal supply chain dependence presents a second challenge. Many of the most effective asymmetric hydrogenation and oxidation catalysts rely on precious metal elements including rhodium, iridium and ruthenium, whose supply is geographically concentrated and subject to significant price volatility. Disruptions in precious metal supply or sharp price increases can materially affect the economics of chiral synthesis operations that rely heavily on these catalyst systems, and developing alternative non-precious metal or organocatalytic routes for key chiral transformations is a significant but resource-intensive response strategy that few producers can pursue independently.

Segmentation Analysis

Global Chiral Chemicals Market Size, 2035

Get Comprehensive Insights on the Market Segmentation in this Report

download Download FREE Sample

By Types

Traditional Separation Method: Traditional separation methods hold approximately 28% of market share, encompassing classical resolution techniques including diastereomeric salt formation, preferential crystallisation and chiral chromatographic separation that physically separate enantiomers from racemic mixtures. Despite being less atom-efficient than asymmetric preparation approaches, these methods remain commercially relevant because they can be applied to a wide range of chemical structures without requiring specialised chiral catalyst development.

Chiral chromatography, operated through simulated moving bed and preparative high-performance liquid chromatography systems, has maintained commercial importance particularly for pharmaceutical applications where regulatory approval timelines create pressure to deliver chiral active pharmaceutical ingredients before asymmetric synthesis routes are fully optimised. Companies including Chiral Technologies and PerkinElmer provide chiral stationary phases and analytical systems that support both production-scale separation and analytical enantiomeric purity verification across pharmaceutical and fine chemical manufacturing operations.

Asymmetric Preparation Method: Asymmetric preparation methods hold the largest market share at approximately 48%, reflecting their position as the preferred production route for high-volume single-enantiomer pharmaceuticals and the primary focus of chiral chemistry innovation investment. These methods use chiral catalysts including transition metal complexes, organocatalysts and chiral auxiliary reagents to create enantiomerically enriched products directly from prochiral starting materials, avoiding the yield losses inherent in resolution-based approaches.

Johnson Matthey, BASF, Solvias and Rhodia are among the leading suppliers of chiral catalyst systems for asymmetric preparation, with each maintaining proprietary ligand and catalyst libraries that serve pharmaceutical and agrochemical customers across a range of key transformation types including hydrogenation, oxidation, aldol reactions and cycloadditions. Continuous process development is progressively improving catalyst turnover numbers and substrate scope, expanding the range of chemical targets accessible through asymmetric preparation at commercially viable cost.

Biological Separation Method: Biological separation methods account for approximately 24% of market share, covering enzymatic resolution of racemic mixtures and the growing field of asymmetric biocatalysis where engineered enzymes produce single-enantiomer products directly. Biocatalytic approaches offer distinctive advantages including high selectivity under mild aqueous conditions, environmental compatibility and the ability to catalyse transformations that are difficult to achieve with conventional chemical catalysts.

Codexis is the leading commercial developer of engineered enzyme systems for pharmaceutical chiral synthesis, and its CodeEvolver protein engineering platform has enabled the development of novel biocatalysts for commercially important chiral transformations including the synthesis of several high-volume pharmaceutical active ingredients. The growing accessibility of AI-assisted protein engineering tools is expanding the number of organisations capable of developing custom biocatalysts, broadening the competitive landscape in the biological separation method segment.

By Applications

Pharmaceuticals: Pharmaceutical applications account for approximately 72% of total chiral chemical demand, driven by the industry's regulatory requirement for enantiomeric purity, the superior clinical profiles of single-enantiomer drugs and the sustained investment in new chiral drug development across multiple therapeutic categories. Chiral chemicals serve pharmaceutical applications across the full value chain from early-stage research intermediates through to commercial scale active pharmaceutical ingredient production.

The pharmaceutical application segment is characterised by the highest quality and documentation requirements of any chiral chemical end market, with purchasers requiring comprehensive analytical data on enantiomeric purity, impurity profiles and process validation across batch-to-batch production. This quality intensity supports premium pricing for pharmaceutical-grade chiral chemicals and creates durable commercial relationships between pharmaceutical manufacturers and qualified chiral chemical suppliers including BASF, Johnson Matthey and Codexis that have invested in the manufacturing and quality systems required to meet pharmaceutical customer expectations.

Agrochemicals: Agrochemical applications account for approximately 20% of chiral chemical market demand, a share that is growing as regulatory pressure and environmental policy drive the agrochemical industry toward single-enantiomer active ingredients that deliver equivalent or superior efficacy at lower application rates. An estimated 18% of new agrochemical active ingredients currently in regulatory review contain chiral centres, reflecting increasing new product development investment in chiral agrochemical active ingredients across crop protection categories.

Bayer, BASF and DowDuPont are among the major agrochemical producers investing in chiral active ingredient development programmes, and their demand for chiral synthesis services and intermediates is expected to grow as these development programmes advance toward commercial registration. The agrochemical application segment is more cost-sensitive than pharmaceuticals but represents a large volume opportunity for chiral chemical producers that can offer competitive production economics for agrochemical-grade enantiomeric purity requirements.

Flavors/Fragrances: Flavor and fragrance applications account for approximately 8% of chiral chemical demand, reflecting the important role of enantiomeric form in determining the sensory characteristics of many flavour and fragrance molecules. The same chiral compound can have dramatically different odour or taste profiles depending on its enantiomeric configuration, and flavour and fragrance producers require chiral chemical inputs with defined enantiomeric purity to achieve consistent product sensory performance.

Chiracon and Strem Chemicals serve the flavour and fragrance segment with chiral intermediates and building blocks used in the synthesis of specific enantiomers of key aroma chemicals. This segment tends to have lower volume requirements than pharmaceuticals or agrochemicals but values consistent enantiomeric purity and sensory performance documentation that enables reproducible flavour and fragrance compound manufacturing.

Regional Outlook

Global Chiral Chemicals Market Share, by Type 2035

Get Comprehensive Insights into the Market’s Size and Growth Trends

download Download FREE Sample

North America

North America holds approximately 36% of global chiral chemicals market share and is the largest regional market. The United States is the dominant market, supported by the world's most active pharmaceutical research and development ecosystem, a well-established regulatory framework for chiral drug purity requirements and a large contract manufacturing sector with extensive chiral synthesis capability. Major producers including Johnson Matthey, Codexis, Chiral Technologies and PerkinElmer serve domestic pharmaceutical, agrochemical and flavour and fragrance customers through both bulk supply and custom synthesis service models.

Canada contributes steady demand from its pharmaceutical manufacturing sector and growing biotechnology industry. Both markets show strong interest in biocatalytic chiral synthesis technologies, and North American pharmaceutical companies are at the forefront of adopting engineered enzyme platforms for chiral active pharmaceutical ingredient production. The region's deep pool of chiral chemistry expertise concentrated in academic institutions and established chemical companies provides a strong talent foundation for continued market leadership.

Europe

Europe accounts for approximately 28% of the global chiral chemicals market. Germany, Switzerland, the United Kingdom, France and the Netherlands are the leading individual markets, each hosting major pharmaceutical manufacturers, speciality chemical companies and contract synthesis organisations with advanced chiral chemistry capabilities. European chiral chemical producers including BASF, Solvias and Rhodia maintain globally competitive positions in asymmetric catalyst development and pharmaceutical-grade chiral intermediate production.

European regulatory standards enforced through the EMA's guidelines on stereoisomeric drug development provide a consistent demand driver for pharmaceutical-grade chiral chemicals across EU member state manufacturing operations. The region's strong chemical engineering and process chemistry expertise supports continued innovation in both asymmetric synthesis and biocatalytic chiral production, and several European universities and research institutes maintain world-leading programmes in asymmetric catalysis that feed the commercial innovation pipeline.

Asia-Pacific

Asia-Pacific holds approximately 26% of global market share and is the fastest-growing regional market. China, Japan, South Korea and India are the dominant markets, with China representing the largest growth opportunity as its pharmaceutical and agrochemical manufacturing sectors rapidly expand their chiral production capability. India's large contract pharmaceutical manufacturing sector is a significant and growing consumer of chiral chemical synthesis services, as Indian API manufacturers increasingly serve global pharmaceutical companies requiring single-enantiomer active ingredients to international quality standards.

Japan's sophisticated pharmaceutical industry and long history of chiral chemistry research make it a technically advanced market with high per-unit chiral chemical value demand. South Korea's active pharmaceutical and agrochemical sectors are also expanding their chiral chemistry investment. Chinese domestic investment in chiral chemical production infrastructure is growing rapidly, driven by both domestic pharmaceutical market development and the country's ambition to expand its position in global pharmaceutical contract manufacturing.

Middle East and Africa

The Middle East and Africa region accounts for approximately 5% of global chiral chemicals market share. The Middle East's pharmaceutical manufacturing sector, primarily concentrated in Israel, Jordan, Saudi Arabia and the United Arab Emirates, generates demand for chiral active pharmaceutical ingredients for both domestic formulation and regional export markets. Israel's well-developed pharmaceutical industry includes established chiral chemistry expertise that serves both domestic production and international supply relationships.

Africa's chiral chemicals market is at an early stage, with demand primarily driven by pharmaceutical formulation operations in South Africa, Egypt, Kenya and Nigeria that source chiral active ingredients from international producers. The development of domestic pharmaceutical manufacturing capacity across the continent, supported by international health agency programmes and growing local investment, is expected to gradually increase regional chiral chemical procurement volumes over the forecast period.

Rest of the World

The Rest of the World segment, which includes Latin America and other markets not covered above, represents approximately 5% of global demand. Brazil, Mexico and Argentina are the largest markets in this segment, with pharmaceutical manufacturing sectors that source chiral active pharmaceutical ingredients primarily from North American, European and Asian suppliers. Brazil's large domestic pharmaceutical market and growing generics manufacturing sector create consistent demand for chiral intermediates and active ingredients.

Latin American agrochemical markets represent a growing opportunity for chiral agrochemical products, as large-scale agricultural economies in Brazil, Argentina and Colombia adopt more sophisticated crop protection strategies that value the environmental performance benefits of single-enantiomer formulations. Currency volatility and import cost structures continue to affect regional market economics, but underlying demand trends support a positive long-term growth outlook for chiral chemical consumption across the region.

List of Top Chiral Chemicals Market Companies

  • BASF
  • Johnson Matthey
  • Solvias
  • Strem Chemicals
  • Bayer
  • Codexis
  • Chiral Technologies
  • Rhodia
  • W. R. Grace
  • PerkinElmer
  • DowDuPont
  • Chiracon

Top 2 Companies with Highest Market Share

  • BASF: BASF holds an estimated 14.6% share of the global chiral chemicals market, supported by its comprehensive portfolio of chiral catalyst systems, its established custom synthesis capability for pharmaceutical and agrochemical customers, its global manufacturing infrastructure and its ongoing investment in biocatalytic and asymmetric synthesis technology development for high-value chiral intermediate production.
  • Johnson Matthey: Johnson Matthey follows with an estimated 12.4% share, leveraging its globally recognised expertise in asymmetric hydrogenation catalyst development, its proprietary chiral ligand and catalyst library serving pharmaceutical API manufacturers worldwide, and its expanding service offering in custom asymmetric synthesis process development for clinical and commercial scale chiral drug production programmes.

Investment Analysis and Opportunities

Investment activity in the chiral chemicals market is concentrated on biocatalytic technology platforms, continuous flow process development and capacity expansion in Asia-Pacific to serve growing regional pharmaceutical manufacturing demand. Life science investors and strategic acquirers are directing capital toward companies with proprietary engineered enzyme libraries, asymmetric catalyst intellectual property and established pharmaceutical customer relationships that provide recurring custom synthesis revenue. The convergence of AI-assisted protein engineering with directed evolution methodology is attracting venture investment into next-generation biocatalysis companies that can accelerate chiral catalyst development timelines for pharmaceutical customers.

The strongest investment opportunities lie in enzymatic asymmetric synthesis technology, chiral process development services for pharmaceutical contract manufacturing organisations and agrochemical sector chiral active ingredient development. Investors should evaluate intellectual property portfolio strength, pharmaceutical customer qualification depth, technology platform versatility across chemical transformation types and manufacturing quality system compliance as primary indicators of competitive positioning and long-term value creation potential in this technically sophisticated and innovation-driven market.

New Product Development

Product development in the chiral chemicals market is advancing primarily through engineered biocatalyst innovation and asymmetric catalyst system optimisation. Codexis and W. R. Grace are at the forefront of developing next-generation enzyme variants capable of catalysing chiral transformations with enantiomeric excess values consistently above 99.5%, with new enzyme families being engineered for commercially important reaction classes including reductive amination, ketoreduction and C-C bond formation that underpin the synthesis of high-priority chiral pharmaceutical intermediates. Continuous flow biocatalysis systems that combine enzyme immobilisation with microreactor technology are also advancing, enabling more efficient and scalable biocatalytic chiral synthesis than batch enzymatic processes allow.

Asymmetric catalyst development continues to advance through the design of more active and selective chiral ligand systems that achieve high enantiomeric excess under less demanding reaction conditions, reducing solvent requirements and improving the environmental footprint of chemical asymmetric synthesis. Johnson Matthey and Solvias are developing second and third-generation versions of commercially important chiral catalyst families with improved substrate scope, longer catalyst lifetime and greater tolerance for the impurity profiles typical of pharmaceutical-scale raw material streams. Computational chemistry and machine learning tools are accelerating catalyst optimisation by enabling virtual screening of large ligand libraries to identify high-probability candidates for experimental evaluation.

Five Recent Developments

Date Company Development
February 2026 Johnson Matthey Johnson Matthey launched an advanced asymmetric hydrogenation catalyst platform, with process validation data demonstrating a 20% improvement in enantiomeric excess consistency across production scale batches compared with the previous generation catalyst system for key pharmaceutical intermediate applications.
April 2026 Codexis Codexis expanded its engineered enzyme platform for pharmaceutical chiral synthesis, with new biocatalyst variants projected to reduce manufacturing steps by approximately 30% for key chiral active pharmaceutical ingredient production routes targeting central nervous system and cardiovascular drug programmes.
June 2026 BASF BASF introduced a new organocatalyst system for enantioselective pharmaceutical intermediate synthesis, achieving enantiomeric excess values above 98% without reliance on precious metal catalyst components, reducing both cost and supply chain concentration risk for customers adopting the new process route.
August 2026 Solvias Solvias expanded its chiral catalyst screening and process development service capacity, adding automated high-throughput asymmetric reaction screening infrastructure projected to increase its annual pharmaceutical customer process development throughput by approximately 25% across its European facilities.
October 2026 Chiral Technologies Chiral Technologies launched a new generation of chiral stationary phases for preparative chromatographic separation, demonstrating a 16% improvement in throughput per unit column volume and enabling more cost-competitive chiral resolution of pharmaceutical intermediates at commercial production scale.

Future Outlook

The chiral chemicals market is positioned for sustained and robust growth driven by the pharmaceutical industry's continued commitment to single-enantiomer drug development, the agrochemical sector's progressive adoption of chiral active ingredients and the technological revolution in biocatalytic synthesis that is making enzymatic chiral production routes commercially compelling across an expanding range of chemical targets. The integration of AI-assisted protein engineering with directed evolution methodology is expected to dramatically accelerate biocatalyst development timelines, enabling more rapid translation of new chiral drug targets into commercially viable enzymatic production processes.

Long-term competitive advantage will belong to producers that combine strong intellectual property positions in chiral catalyst and biocatalyst technology with pharmaceutical-grade manufacturing quality systems, deep customer relationships in pharmaceutical and agrochemical development programmes and the process development capability to translate laboratory chiral chemistry into cost-competitive commercial production. Companies that invest in continuous flow manufacturing integration, AI-assisted catalyst optimisation and emerging market manufacturing capacity are expected to capture a disproportionate share of value as the global chiral chemicals market expands and the technical requirements of pharmaceutical and agrochemical customers continue to advance.

Chiral Chemicals Market Report Coverage

REPORT COVERAGE DETAILS

Market Size Value In

USD 80438.6 Million in 2026

Market Size Value By

USD 213478.25 Million by 2035

Growth Rate

CAGR of 11.45% from 2026-2035

Forecast Period

2026 - 2035

Base Year

2025

Historical Data Available

Yes

Regional Scope

Global

Segments Covered

By Type :

  • Traditional Separation Method
  • Asymmetric Preparation Method
  • Biological Separation Method

By Application :

  • Pharmaceuticals
  • Agrochemicals
  • Flavors/Fragrances

To Understand the Detailed Market Report Scope & Segmentation

download Download FREE Sample

Frequently Asked Questions

The global Chiral Chemicals Market is expected to reach USD 213478.25 Million by 2035.

The Chiral Chemicals Market is expected to exhibit a CAGR of 11.45% by 2035.

BASF, Johnson Matthey, Solvias, Strem Chemicals, Bayer, Codexis, Chiral Technologies, Rhodia, W. R. Grace, PerkinElmer, DowDuPont, Chiracon

In 2026, the Chiral Chemicals Market value will reach at USD 80438.6 Million.

faq right

Our Clients

Captcha refresh

Trusted & Certified